Adagene Inc. (ADAG)

NASDAQ: ADAG · Real-Time Price · USD

3.000

+0.160 (5.63%)

Mar 9, 2026, 2:04 PM EDT - Market open

Adagene Employees

Adagene had 138 employees as of December 31, 2024. The number of employees decreased by 36 or -20.69% compared to the previous year.

Employees

138

Change (1Y)

-36

Growth (1Y)

-20.69%

Revenue / Employee

$748

Profits / Employee

-$216,592

Market Cap

141.39M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	138	-36	-20.69%
Dec 31, 2023	174	-74	-29.84%
Dec 31, 2022	248	-11	-4.25%
Dec 31, 2021	259	61	30.81%
Dec 31, 2020	198	-	-

Related Stocks

Company Name	Employees
MacroGenics	341
Sangamo Therapeutics	183
Artiva Biotherapeutics	106
Connect Biopharma Holdings	62
Spero Therapeutics	32
Cardiff Oncology	31
Unicycive Therapeutics	23

Employee Rankings

ADAG News

20 days ago - Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
6 weeks ago - Adagene Provides Business Update and 2026 Objectives - GlobeNewsWire
2 months ago - Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) - GlobeNewsWire
4 months ago - Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - GlobeNewsWire
4 months ago - Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - GlobeNewsWire
6 months ago - Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - GlobeNewsWire
6 months ago - Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - GlobeNewsWire
6 months ago - Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - GlobeNewsWire